FDA Inspection 1187325 — GSK LLC (GlaxoSmithKline)
The FDA completed an inspection of GSK LLC (GlaxoSmithKline) on October 24, 2022 in Collegeville, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 24, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Collegeville, PA (United States)
Additional Details
Sponsor, Contract Research Organization